TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31814522
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation protocol (10 minutes)
Study: 27761668
Drug: Extraoral infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraoral infrared light therapy for 20 min daily with at least 80% compliance (n=20)
Study: 26362959
Drug: Paracetamol-codeine phosphate
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-codeine phosphate (300 mg + 30 mg)
Study: 26362959
Drug: Naproxen sodium-codeine
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen sodium-codeine phosphate (550 mg + 30 mg)
Study: 22672359
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (n=14)
Study: 22672359
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (n=13)
Study: 21720655
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% applied twice daily
Study: 21720655
Drug: Topical medical
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medical device cream applied three times daily
Study: 19179127
Drug: Bismuth 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth 240 mg bis in die for 14 days combined with amoxicillin 1g plus metronidazole 250 mg tris in die for the first week
Study: 19179127
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once a day for 14 days combined with amoxicillin 1g plus metronidazole 250 mg tris in die for the first week
Study: 3891436
Drug: Topical antihistaminics
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antihistaminics
Study: 19151050
Drug: Topical levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobupivacaine 0.75%
Study: 19151050
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 2%
Study: 15054437
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (VA) supplementation (210 micromol) and deworming (400 mg albendazole) in Group 1 (VA administered > or = 4 months before baseline)
Study: 15054437
Drug: VA delivered
Normalized name: VP/VA COPOLYMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA delivered through the public health system in Group 2 (VA administered < or = 1 month before baseline)
Study: 9071556
Drug: 2.5% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% hydrocortisone ointment
Study: 7527736
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CAP or modified M-VAC)
Study: 7527736
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (modified M-VAC or MEC)
Study: 4391702
Drug: Alprenolol 100
Normalized name: alprenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol 100 mg four times daily
Study: 4391702
Drug: Pentanitrol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentanitrol 30 mg four times daily
Study: 23388588
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg 30 minutes before bedtime for 6 weeks
Study: 23388588
Drug: Clonazepam 2
Normalized name: clonazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 2 mg at night (with gradual titration over 4 weeks from 0.5 mg)
Study: 19045977
Drug: 8-week Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week Internet-based cognitive behavior therapy program with minimal therapist contact via e-mail and weekly telephone calls of less than 15 min
Study: 15949095
Drug: 0.05% solution
Normalized name: Equate Nasal Spray 0.05% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% solution of betamethasone dipropionate (BD)
Study: 14627440
Drug: Isoflavones tablets
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones tablets
Study: 9380298
Drug: Estrogens (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogens (0.15 or 0.3 or 0.625 mg)
Study: 8436494
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (100mg, two capsules a day for 15 days)
Study: 27568900
Drug: Zolpidem nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem nasal spray 1.75 mg
Study: 27568900
Drug: Zolpidem nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem nasal spray 3.5 mg
Study: 27568900
Drug: Zolpidem nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem nasal spray 5.0 mg
Study: 27568900
Drug: Zolpidem nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem nasal spray (1.75 mg, 3.5 mg, 5.0 mg)
Study: 27568900
Drug: Zolpidem nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem nasal spray
Study: 21152784
Drug: cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream with Belides, Emblica and Licorice 7%, applied twice a day
Study: 21152784
Drug: cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream with Hydroquinone 2%, used at night
Study: 12151444
Drug: Physician-Administered Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-Administered Sedation (PAS)
Study: 8622041
Drug: Protocol 77-04
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 77-04 (15 cycles of CTX, ADR, PRED, VCR, high-dose MTX, and IT therapy)
Study: 3780987
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving treatment (tumorectomy followed by radiotherapy)
Study: 3780987
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (mastectomy and breast conserving treatment)
Study: 25088437
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (target HbA1c less than 42 mmol/mol or less than 6·0%)
Study: 25088437
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (target HbA1c 53‐63 mmol/mol or 7·0‐7·9%)
Study: 15980686
Drug: Indinavir (IDV)/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (IDV)/ritonavir (RTV)‐containing highly active antiretroviral (ARV) therapy regimens
Study: 12705178
Drug: Triclabendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclabendazole (10 mg/kg body weight, two consecutive oral doses)
Study: 12705178
Drug: Triclabendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclabendazole (10 mg/kg body weight) + Vitamin C (1000 mg/day) + Vitamin E (600 mg/day) for two months
Study: 6784224
Drug: Bacampicillin 400
Normalized name: bacampicillin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 400 mg twice a day
Study: 6784224
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 250 mg four times a day
Study: 6784224
Drug: Amoxicillin 250
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 250 mg every 8 hr
Study: 30698316
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus CABG (MED/CABG)
Study: 30698316
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between CCI score and treatment effect
Study: 26346470
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified doogh (FD), containing 12.5 μg/250 ml, taken twice a day for 12 weeks
Study: 26346470
Drug: Plain doogh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain doogh (PD), containing no vitamin D, taken twice a day for 12 weeks
Study: 17965789
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation (lactulose 2 days before surgery and rectal enema on the day of surgery)
Study: 17965789
Drug: No bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bowel preparation (Control Group II)
Study: 15379121
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy consisting of 5-day courses of cytostatic drugs alternating or not alternating with 5-day courses of ATRA
Study: 26287319
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PCF) with surgery
Study: 26287319
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy alone
Study: 21076271
Drug: HBV-active antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV-active antiretroviral therapy (ART) for 48 weeks
Study: 12712958
Drug: AIDSVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX vaccine
Study: 10736331
Drug: Dietary diacylglycerol
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary diacylglycerol (DG) - 10 g/d
Study: 10736331
Drug: Triacylglycerol (TG)
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triacylglycerol (TG) - 10 g/d (control)
Study: 8737101
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g MgSO4 bolus followed by 4 g MgSO4 for 24 h
Study: 8737101
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g MgSO4 bolus followed by 14 g MgSO4 for 24 h
Study: 1560192
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement treatment
Study: 2862464
Drug: Dry powdered
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powdered surfactant (25 mg) insufflated through the endotracheal tube
Study: 17899018
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxycodone
Study: 23163142
Drug: Qudu Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qudu Granule (QG), orally taken, 5 g each time, 3 times a day for over 12 months.
Study: 23163142
Drug: Niaoduqing granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaoduqing granule (NG), orally taken, 5 g each time, 3 times a day for over 12 months.
Study: 20380284
Drug: Chemo-radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-radiotherapy with Temodal (75 mg/m2)
Study: 20380284
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy only (60 Gy, fractionated into 5 x 2 Gy weekly)
Study: 15653517
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus strain L-92 (100 mL of heat-treated fermented milk)
Study: 10235522
Drug: Blood cardioplegia
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cardioplegia containing 2 mM adenosine and adenosine infusion (200 microg/kg/min) before and after aortic crossclamp removal
Study: 8909453
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human ciliary neurotrophic factor (rhCNTF) at doses ranging from 2 to 100 micrograms/kg
Study: 8909453
Drug: daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily subcutaneous rhCNTF at doses < or = 5 micrograms/kg/day
Study: 8909453
Drug: daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily subcutaneous rhCNTF at higher doses
Study: 1810522
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% meclofenamic acid gel
Study: 1810522
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium meclofenamate capsules
Study: 1810522
Drug: Sodium naproxen
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium naproxen capsules
Study: 6406441
Drug: Bupropion 150
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 150 mg/day
Study: 6406435
Drug: Bupropion 450
Normalized name: buPROPion 450 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 450 mg/day
Study: 22869581
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate monotherapy at 2 mg/kg/day for 7 days
Study: 22869581
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate monotherapy at 4 mg/kg/day for 7 days
Study: 22869581
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate monotherapy at 6 mg/kg/day for 7 days
Study: 22869581
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate monotherapy
Study: 17055329
Drug: APO (apomorphine)
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APO (apomorphine) at typically effective dose (TED)
Study: 14530901
Drug: Memantine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (0 mg)
Study: 14530901
Drug: Memantine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (15 mg)
Study: 9710711
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 35 mg ethinylestradiol and 2 mg cyproterone acetate
Study: 9710711
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 30 mg ethinylestradiol and 150 mg desogestrel
Study: 7663660
Drug: Aerosolised rhDNase
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolised rhDNase 2.5 mg twice daily
Study: 7663660
Drug: Aerosolised rhDNase
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolised rhDNase 2.5 mg twice daily (open-label phase)
Study: 27869649
Drug: Calcipotriol (0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (0.005% ointment) combined with 5-fluorouracil (5% cream)
Study: 27869649
Drug: Vaseline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline plus 5-fluorouracil (5% cream)
Study: 21593096
Drug: Full length
Normalized name: antihemophilic factor (FVIII) rec, full length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full length 5 degree lateral wedged insoles worn daily for 12 months
Study: 21593096
Drug: Flat control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat control insoles worn daily for 12 months
Study: 9215091
Drug: Valaciclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (500 mg once daily)
Study: 8314294
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime i.v. as a single bolus 20 minutes before surgical incision
Study: 8314294
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime i.v. injected 20 minutes after incision
Study: 31623493
Drug: Pregabalin controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin controlled-release (CR) 165 and 330 mg/day
Study: 26626148
Drug: Low-dose GTP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GTP (500 mg)
Study: 26626148
Drug: High-dose GTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GTP (1,000 mg)
Study: 26626148
Drug: GTP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTP treatment (both doses)
Study: 23300343
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (MMC) 40 mg within 6 hours after TURBT
Study: 9212308
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (P)
Study: 8484622
Drug: Max‐EPA (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max‐EPA (3.2 g/day eicosapentaenoic acid)
Study: 29449506
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg subcutaneously every other week for 6 weeks
Study: 26910749
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dydrogesterone and hydroxyprogesterone caproate
Study: 21246845
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on syndrome differentiation, using Ashi points and specific acupuncture points (Yanglingquan, Taichong, Zusanli)
Study: 21246845
Drug: Muscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscular injection of Bucinnazine
Study: 21246845
Drug: Medication (Bucinnazine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Bucinnazine)
Study: 18441320
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg > 6 h before CAG (group A)
Study: 18441320
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg in the cath-lab after CAG only in case of PCI (group B)
Study: 12063152
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 50 weeks
Study: 9734550
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 38 weeks and then 12 weeks of placebo
Study: 9734550
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 14 weeks and then 36 weeks of placebo
Study: 7925206
Drug: Rocuronium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.75 mg kg‐1
Study: 8556998
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg kg‐1
Study: 3287909
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg for two days
Study: 3287909
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg for five days
Study: 3287909
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg four times per day
Study: 3287909
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg for one day
Study: 16571878
Drug: 90 microg
Normalized name: Linaclotide 290 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 microg subvirion influenza A (H5N1) vaccine
Study: 16571878
Drug: 45 microg
Normalized name: Linaclotide 145 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 microg subvirion influenza A (H5N1) vaccine
Study: 16571878
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg subvirion influenza A (H5N1) vaccine
Study: 16571878
Drug: 7.5 microg
Normalized name: Levonorgestrel 37.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 microg subvirion influenza A (H5N1) vaccine
Study: 10681608
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 microg/g) combined with twice weekly broad-band UVB
Study: 9080870
Drug: Chloroquine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (5 mg base/kg, n = 20)
Study: 9080870
Drug: Primaquine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.5 mg base/kg, n = 30)
Study: 8442748
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy
Study: 22333328
Drug: Naltrexone (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (oral, Revia)
Study: 18600342
Drug: Harmonic Scalpel
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Harmonic Scalpel Group (HS-G)
Study: 18600342
Drug: Clip-Ligation Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clip-Ligation Group (CL-G)
Study: 16928842
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg tablets given twice daily
Study: 16928842
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg extended-release tablets given once daily
Study: 6990674
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg
Study: 30807328
Drug: Oral Sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sucrose
Study: 26874258
Drug: Neostigmine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 40 μg.kg(‐1)
Study: 26874258
Drug: Neostigmine 0
Normalized name: neostigmine 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0 μg.kg(‐1)
Study: 26874258
Drug: Neostigmine 10
Normalized name: neostigmine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 10 μg.kg(‐1)
Study: 26874258
Drug: Neostigmine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 20 μg.kg(‐1)